Schering AG Germany has agreed to acquire the LEUKINE business from Immunex Corp., which is merging with Amgen Inc. The deal, announced May 2, is worth $380 million.
LEUKINE is a man-made protein that increases the growth of white blood cells and is used to ward off infectious diseases while treating cancer.
Berlin-based Sch...
LEUKINE is a man-made protein that increases the growth of white blood cells and is used to ward off infectious diseases while treating cancer.
Berlin-based Sch...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In